"The primary efficacy endpoint will be trajectory of PaO2/FiO2 ratio (a measure of hypoxemia, a low level of oxygen in the blood caused by compromised lung function) by Day 7. Safety and tolerability up to Day 28 will also be a primary endpoint."
Fast readout here.
and data for CRS/ Sepsis too and implications for IPF undergoing Potency tests currently at Monash.
Ann: First Patient Enrolled in Cynata MEND Clinical Trial, page-4
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.68M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 22.5¢ | $30.97K | 137.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8412 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 16723 | 1 |
View Market Depth
| Last trade - 13.24pm 19/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |